Trial profile and demographic characteristics of the participants
ADENOVIRUS
Of the 419 participants, 418 (99.76%) completed the 12-month follow-up, and all (100.00%) were involved in the safety analysis cohort. In the sub-cohort of antibody persistence analysis, 120 (100.00%) participants donated blood samples on day 28 after the booster dose, and 118 (98.33%), 114 (95.00%), and 91 (75.83%) participants contributed blood samples at months 3, 6, and 12, respectively (Study profile. Ad5-nCoV = orally administered aerosolised adenovirus type-5 vector-based COVID-19 vaccine carrying full-length SARS-CoV-2 spike gene. CoronaVac = intramuscularly administered inactivated whole-virion SARS-CoV-2 vaccine.